联合激素避孕药与二甲双胍对高雄激素性多囊卵巢综合征合并肥胖女性代谢综合征的影响:COMET-PCOS随机临床试验
COMET-PCOS多中心双盲双模拟随机试验纳入240例高雄激素性多囊卵巢综合征合并超重/肥胖女性,比较低剂量联合口服避孕药、二甲双胍XR或两者联用24周对代谢综合征患病率的影响。完成试验的169例中,三组代谢综合征患病率无显著差异(校正P=0.26);低剂量联合口服避孕药有效管理多囊卵巢综合征症状且未增加代谢综合征患病率。
要点
- 低剂量联合口服避孕药组代谢综合征患病率28.8%(17/59),二甲双胍组26.2%(17/65),联合组28.6%(17/59),组间趋势无显著差异(校正P=0.26)。
- 联合口服避孕药组腰围平均变化-2.23 cm(95%CI [-3.98, -0.49];P=0.01)、BMI平均变化-0.49 kg/m2(95%CI [-0.88, -0.10];P=0.01)、DXA安卓脂肪量平均变化-167 g(95%CI [-264, -71];P<0.001)较基线下降。
- 二甲双胍组和联合组多数参与者(>64%)报告腹泻,联合口服避孕药组24.1%报告子宫出血。
核心结论
- 在高雄激素性多囊卵巢综合征合并超重/肥胖的参与者中,低剂量联合口服避孕药有效管理多囊卵巢综合征症状且未增加代谢综合征患病率。
- 研究结果挑战了当前单独使用二甲双胍或联合口服避孕药以降低心脏代谢风险的实践。
研究设计与样本
- 多中心、双盲、双模拟随机试验(COMET-PCOS),纳入年龄≥18且≤40岁、BMI≥25且≤48 kg/m2、符合鹿特丹标准的高雄激素性多囊卵巢综合征参与者。
- 参与者按1:1:1随机分配至24周低剂量联合口服避孕药(20 μg炔雌醇/0.15 mg去氧孕烯)、二甲双胍XR(2,000 mg)或两者联合组。
- 共240例随机分配,联合口服避孕药组79例中20例脱落,二甲双胍组81例中16例脱落,联合组80例中17例脱落;169例(70.4%)在2018年1月至2023年6月间完成试验(平均年龄29.5岁;平均BMI 35.6 kg/m2;70%为白人,23%为黑人)。
主要发现
- 基线时代谢综合征总体患病率为31%,组间相当。
- 研究结束时代谢综合征患病率:二甲双胍组26.2%(17/65),联合组28.6%(17/59),联合口服避孕药组28.8%(17/59),组间代谢综合征患病率趋势无显著差异(校正P=0.26)。
- 联合口服避孕药组研究期间腰围平均变化-2.23 cm(95%CI [-3.98, -0.49];P=0.01)、BMI平均变化-0.49 kg/m2(95%CI [-0.88, -0.10];P=0.01)、DXA测量的安卓脂肪量平均变化-167 g(95%CI [-264, -71];P<0.001)下降;二甲双胍单药组这些参数与基线相比无统计学显著变化。
- 二甲双胍组和联合组多数参与者(>64%)报告腹泻,联合口服避孕药组24.1%报告子宫出血。
临床怎么用
- 作者认为,在肥胖的高雄激素性多囊卵巢综合征女性中,低剂量联合口服避孕药可有效管理多囊卵巢综合征症状且未增加代谢综合征患病率。
- 作者指出,研究结果挑战了当前单独使用二甲双胍或联合口服避孕药以降低心脏代谢风险的实践。
局限性
- 研究的主要方法学局限性是可能缺乏检测次要结局差异的效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk-to-benefit ratio of using combined oral contraceptive pills (COCPs) and/or metformin for comprehensive management of polycystic ovary syndrome (PCOS) in women with obesity is unclear. As there is a lack of robust evidence on the impact of these first-line medications on cardiovascular disease (CVD) risk, we compared the effect of COCPs, metformin or both on prevalence of metabolic syndrome (MetS) in participants with hyperandrogenic PCOS and hypothesized that COCPs would increase prevalence of MetS while metformin would decrease prevalence of MetS. METHODS AND FINDINGS: We conducted a multicenter, double-blind, double-dummy, randomized trial (COMET-PCOS) in participants between ages ≥18 and ≤40 years and body mass index (BMI) ≥25 kg/m2 and ≤ 48 kg/m2 with hyperandrogenic PCOS (defined by the Rotterdam criteria). Participants were randomized 1:1:1 to 24 weeks of low-dose COCPs (20 μg ethinyl estradiol/0.15 mg desogestrol), metforminXR (2,000 mg), or both (Combined). The primary outcome, assessed by intention-to-treat analysis, was the effect of the different treatment groups on the prevalence of MetS at the end of study. The analytical model included site, race, and the presence or absence of MetS at the screening visit as covariates. The secondary outcomes included changes in each component of MetS (TG, HDL-C, BP, WC, and fasting glucose levels) over the study period. Of the 240 participants randomly assigned, 20 out of 79 in the COCP group, 16 out of 81 in the metformin group, and 17 out of 80 in the combined group dropped out of the study. A total of 169 participants (70.4%) completed the trial between January 2018 and June 2023 (mean age: 29.5 years; mean BMI: 35.6 kg/m2; 70% were White and 23% were Black). The overall prevalence of MetS was 31% at baseline and comparable across groups. At the end of the study, the prevalence of MetS was 26.2% (17/65) in the metformin group, 28.6% (17/59) in the Combined group, and 28.8% (17/59) in COCP group with no significant difference in trend of MetS prevalence between groups (adjusted p = 0.26). Waist circumference (mean change (MC) -2.23 cm; 95% CI [-3.98, -0.49]; p = 0.01), BMI (MC -0.49 kg/m2; 95% CI [-0.88, -0.10]; p = 0.01), and android fat mass measured by DXA (MC -167 g; 95% CI [-264, -71[; p < 0.001) decreased in the COCP group over the study period whilst there was no statistically significant changes in these parameters in the metformin only group when compared to baseline.. In the metformin and Combined groups, the majority of participants (>64%) reported diarrhea, while 24.1% in the COCP group reported uterine bleeding. The main methodologic limitation of the study is the potential lack of power to detect differences in secondary outcomes. CONCLUSIONS: In participants with hyperandrogenic PCOS and overweight/obesity, low-dose COCPs effectively managed PCOS symptoms without increasing prevalence of MetS. Our findings challenge the current practice of using metformin alone or with COCPs for lowering cardiometabolic risk. TRIAL REGISTRATION: ClinicalTrials.Gov Identifier: NCT03229057.
引用
- Dokras A, Coutifaris C, Remaley AT, et al. Impact of combined hormonal contraceptives and metformin on metabolic syndrome in women with hyperandrogenic polycystic ovary syndrome and obesity: The COMET-PCOS randomized clinical trial. PLoS Med. 2025. PMID: 41359669. doi:10.1371/journal.pmed.1004662
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。